SUBSCRIBE
SUBSCRIBE

Zai Lab (US) LLC

NEWS
Business
Zai Lab to Increase US Presence with New Location in Cambridge
Zai Lab Limited calls itself a growing global biopharmaceutical company and is continuing to live up to that claim with its latest expansion announcement.
September 20, 2021
 · 
1 min read
 · 
Ellen Bombela
Business
Biopharma Companies Entering 2021 With New Collabs, Partnerships
Here’s a run-down of some of the most recent collaboration announcements this week.
January 8, 2021
 · 
4 min read
 · 
Brandon May
Business
BioSpace Movers & Shakers. Dec. 4
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
December 3, 2020
 · 
7 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Press Releases
Zai Lab Establishes Oncology Scientific Advisory Board
August 14, 2025
 · 
4 min read
Press Releases
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
August 7, 2025
 · 
19 min read
Press Releases
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
 · 
1 min read
Press Releases
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
 · 
8 min read
Press Releases
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 16, 2025
 · 
5 min read
Press Releases
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
June 2, 2025
 · 
10 min read
Press Releases
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
June 2, 2025
 · 
12 min read
Press Releases
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
May 19, 2025
 · 
5 min read
Press Releases
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
May 8, 2025
 · 
19 min read
Press Releases
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
April 24, 2025
 · 
6 min read
Load More